A NOVEL NONPEPTIDE CGRP RECEPTOR ANTAGONIST, 'COMPOUND 1' (WO98/11128) IS A HIGH AFFINITY COMPETITIVE ANTAGONIST AT THE CGRP₁ RECEPTOR IN HUMAN CORONARY ARTERIES

P. Hasbak^{a,b}, O. Saetrum Opgaard^c, K. Eskesen^a, S. Schifter^b, H. Arendrup^d, J. Longmore^e,
and L. Edvinsson^a

^aDepartment of Clinical Experimental Research, University Hospital of Copenhagen, Glostrup, Denmark; ^bDepartment of Clinical Physiology and Nuclear Medicine, University Hospital of Copenhagen, Glostrup, Denmark; ^cDepartment of Pharmacology, College of Medicine, University of California at Irvine, Irvine, CA; ^dDepartment of Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark; ^eMerck Sharp & Dohme, Neuroscience Research Centre, Harlow, Essex, U.K.

Functional CGRP and adrenomedullin receptors appear to consist of at least three different kinds of proteins: the calcitonin receptor-like receptor (CRLR), receptor-activity-modifying protein (RAMPs), and the receptor component protein (RCP) that couples the receptor to the cellular signal transduction pathway.

Using reverse transcriptase - polymerase chain reaction the presence of mRNA sequences encoding CRLR, RCP, and the three types of human RAMP that have been cloned were demonstrated in human left anterior descending (LAD) coronary arteries.

Relaxant responses were studied on isolated segments of LAD after precontraction with U46619 (10^{-7} M). The human peptides α CGRP, AM, and amylin induced relaxation with pEC₅₀ values of 8.2 ± 0.2 , 6.9 ± 0.1 , and 6.3 ± 0.2 M (mean $\pm$ S.E.M.), respectively.

The antagonistic properties of a novel nonpeptide CGRP antagonist 'Compound 1' (WO98/11128) were compared to the well-known CGRP₁ receptor antagonist α CGRP₈₋₃₇. Preincubation with α CGRP₈₋₃₇ (10^{-7} to 10^{-5} M) and 'Compound 1' (10^{-7} to 10^{-5} M) caused a dose-dependent rightward shift of the concentration-response curves for α CGRP. The pA₂ values were 7.3 and 7.0, respectively.

Preincubation with α CGRP₈₋₃₇ (10^{-6} M) and 'Compound 1' (10^{-6} M) caused significant rightward shift of the concentration-response curves for AM and amylin. Preincubation with AM₂₂₋₅₂ (10^{-6} M) had no significant antagonistic effect.

In conclusion, mRNA for the components forming CGRP and AM receptors were present in the human LAD. α CGRP, AM, and amylin mediated vasorelaxation via the CGRP₁ receptor. Compound 1 acted as a selective nonpeptide antagonist at the CGRP receptor and could thus become a tool for the study of CGRP-mediated functional responses in human tissue.